Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients With liver cirrhosis

<jats:sec> <jats:title/> <jats:p> <jats:bold>Entecavir is a potent antiviral agent with high genetic barrier to resistance, hence it is currently recommended as first-line antiviral therapy for chronic hepatitis B (CHB). The aim of this study was to investigate the efficacy of entecavir on clinical outcomes and deaths. It was a retrospective-prospective cohort study based on two cohorts of patients. The entecavir cohort included consecutive CHB patients who had received entecavir 0.5 mg/day for at least 12 months. The historical control cohort included untreated patients recruited since 1997 who underwent routine clinical care. The primary outcome was the 5-year cumulative probability of hepatic events, defined as any cirrhotic complications, hepatocellular carcinoma (HCC), and/or liver-related mortality. A total of 1,446 entecavir-treated patients (72% men; age, 51 ± 12 years; follow-up, 36 ± 13 months) and 424 treatment-naïve patients (65% men; age, 41 ± 13 years; follow-up, 114 ± 31 months) were studied. Overall, there was no difference in hepatic events between the entecavir and control cohorts. Among patients with liver cirrhosis (482 entecavir-treated, 69 treatment-naïve), entecavir-treated patients had reduced risks of all clinical outcomes when compared with treatment-naïve patients with cirrhosis after adjusted for model for end-stage liver disease score: hepatic events (hazard ratio [HR], 0.51; 95% confidence interval [CI], 0.34-0.78;</jats:bold> <jats:bold> P </jats:bold> <jats:bold>= 0.002), HCC (HR, 0.55; 95% CI, 0.31-0.99;</jats:bold> <jats:bold> P </jats:bold> <jats:bold>= 0.049), liver-related mortality (HR, 0.26; 95% CI, 0.13-0.55;</jats:bold> <jats:bold> P </jats:bold> <jats:bold>< 0.001), and all-cause mortality (HR, 0.34; 95% CI, 0.18-0.62;</jats:bold> <jats:bold> P </jats:bold> <jats:bold>< 0.001). Entecavir-treated patients with cirrhosis who failed to achieve undetectable hepatitis B virus DNA (105/482 [22%]) had comparable risk of hepatic events as the untreated patients.</jats:bold> </jats:p> </jats:sec> <jats:sec> <jats:title>Conclusion:</jats:title> <jats:p> <jats:bold>Entecavir therapy reduces the risks of hepatic events, HCC, liver-related and all-cause mortality of CHB patients with liver cirrhosis in 5 years, particularly among those who had maintained viral suppression. (Hepatology 2013;58:1537–1547)</jats:bold> </jats:p> </jats:sec>